We were not able to consistently demonstrate FLT3 expression in our ETP-ALL models (data not shown); therefore, we did not pursue further investigation of this pathway as an alternative target for MRX-2843 in this context. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.